Curanex Pharmaceuticals announces 1-for-20 reverse stock split effective Aug 20, 2026

Curanex Pharmaceuticals Inc

1-for-20 reverse stock split effective 12:01 a.m. PT on Aug 20, 2026; Nasdaq trading begins split-adjusted that day.
Pre-split shares ~31,364,812; post-split ~1,568,241 shares outstanding.
Purpose: regain compliance with Nasdaq's $1.00 minimum bid price rule (Listing Rule 5550(a)(2)).
No fractional shares; fractional interests rounded up to whole share; new CUSIP number assigned.
Authorized shares remain 475,000,000; par value $0.0001 unchanged; equity awards proportionally adjusted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.